Your institution may have access to this item. Find your institution then sign in to continue.
Title
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
A letter to the editor is presented regarding the effect of pre-transplant remission status on high dose therapy and autologous transplantation (HDT-AT) clinical outcomes in multiple myeloma (MM) patients.